tetano
Editor, Senior Moderator
Am J Transl Res
. 2022 Mar 15;14(3):2063-2072.
eCollection 2022.
Proposed protocol for the investigation of the safety and efficacy of the COVID-19 vaccine for patients with psychosis, with pilot safety findings from a Chinese psychiatrist's self-experiment
Chongguang Lin[SUP] 1 [/SUP], Tao Fang[SUP] 2 [/SUP], Jiayue Chen[SUP] 2 [/SUP], Qianchen Li[SUP] 3 [/SUP], Weiliang Yang[SUP] 4 [/SUP], Cong Yao[SUP] 4 [/SUP], Lina Wang[SUP] 4 [/SUP], Yun Sun[SUP] 4 [/SUP], Ziyao Cai[SUP] 1 [/SUP], Jing Ping[SUP] 1 [/SUP], Ce Chen[SUP] 1 [/SUP], Langlang Cheng[SUP] 1 [/SUP], Jinjing Zhu[SUP] 1 [/SUP], Guangdong Chen[SUP] 1 [/SUP], Peiwei Shan[SUP] 1 [/SUP], Chunmian Chen[SUP] 1 [/SUP], Xiaodong Lin[SUP] 1 [/SUP], Hongjun Tian[SUP] 2 [/SUP], Chuanjun Zhuo[SUP] 2 [/SUP]
Affiliations
Abstract
We present a study protocol designed to test the safety and efficacy of the 2019 coronavirus disease (COVID-19) vaccine in patients with major psychotic disease. A secondary objective is to investigate optional vaccination methods for these patients. In a self-experiment, a Chinese psychiatrist examined the safety and efficacy of the COVID-19 vaccine under clinical use of typical antipsychotic agents and sedatives (olanzapine, duloxetine, and diazepam). For patients with extremely drug-resistant conditions, the safety of the COVID-19 vaccine under electroconvulsive therapy was also investigated. The entire study process was recorded on high-definition video. This clinical study protocol is, to our knowledge, the first of its kind. Our findings will shed new light on the protection of patients with psychotic diseases from COVID-19 infection. The protocol was registered at Chinese clinical trial registry (www.chictr.org.cn, ChiCTR2100051297).
Keywords: COVID-19 vaccine; diazepam; duloxetine; electroconvulsive therapy; olanzapine; psychotic disease.
. 2022 Mar 15;14(3):2063-2072.
eCollection 2022.
Proposed protocol for the investigation of the safety and efficacy of the COVID-19 vaccine for patients with psychosis, with pilot safety findings from a Chinese psychiatrist's self-experiment
Chongguang Lin[SUP] 1 [/SUP], Tao Fang[SUP] 2 [/SUP], Jiayue Chen[SUP] 2 [/SUP], Qianchen Li[SUP] 3 [/SUP], Weiliang Yang[SUP] 4 [/SUP], Cong Yao[SUP] 4 [/SUP], Lina Wang[SUP] 4 [/SUP], Yun Sun[SUP] 4 [/SUP], Ziyao Cai[SUP] 1 [/SUP], Jing Ping[SUP] 1 [/SUP], Ce Chen[SUP] 1 [/SUP], Langlang Cheng[SUP] 1 [/SUP], Jinjing Zhu[SUP] 1 [/SUP], Guangdong Chen[SUP] 1 [/SUP], Peiwei Shan[SUP] 1 [/SUP], Chunmian Chen[SUP] 1 [/SUP], Xiaodong Lin[SUP] 1 [/SUP], Hongjun Tian[SUP] 2 [/SUP], Chuanjun Zhuo[SUP] 2 [/SUP]
Affiliations
- PMID: 35422934
- PMCID: PMC8991108
Abstract
We present a study protocol designed to test the safety and efficacy of the 2019 coronavirus disease (COVID-19) vaccine in patients with major psychotic disease. A secondary objective is to investigate optional vaccination methods for these patients. In a self-experiment, a Chinese psychiatrist examined the safety and efficacy of the COVID-19 vaccine under clinical use of typical antipsychotic agents and sedatives (olanzapine, duloxetine, and diazepam). For patients with extremely drug-resistant conditions, the safety of the COVID-19 vaccine under electroconvulsive therapy was also investigated. The entire study process was recorded on high-definition video. This clinical study protocol is, to our knowledge, the first of its kind. Our findings will shed new light on the protection of patients with psychotic diseases from COVID-19 infection. The protocol was registered at Chinese clinical trial registry (www.chictr.org.cn, ChiCTR2100051297).
Keywords: COVID-19 vaccine; diazepam; duloxetine; electroconvulsive therapy; olanzapine; psychotic disease.